Pharmaceutical

J&J seeks expanded approvals for paediatric HIV-1 therapy

Johnson & Johnson has sought approval from the US FDA for the use of its HIV-1 t...

AstraZeneca completes Fusion Pharmaceuticals acquisition

AstraZeneca has announced the conclusion of its acquisition of clinical-stage bi...

Climate change may aggravate multiple sclerosis

A June 2024 literature review has revealed that climate change has the potential...

Bluejay touts positive data for chronic hepatitis D tre...

The biopharma shared preliminary Phase II data at EASL for its IgG1 monoclonal a...

Scientists push for ‘greener’ drugs in published study

5 June marks World Environment Day, an annual celebration that encourages global...

FDA hearing set to discuss advisory committee members’ ...

FDA officials outline what to expect at the upcoming hearing on AdComs, and elab...

Bio-Sourcing and Afrigen Biologics partner on biomanufa...

Belgian biotech, Bio-Sourcing, and Cape Town based company, Afrigen Biologics, h...

Be Bio’s haemophilia B treatment gains FDA orphan drug ...

The US FDA has granted orphan drug designation to Be Biopharma’s (Be Bio) BE-101...

MDMA therapy wait goes on as FDA panel rejects Lykos’ P...

An FDA advisory committee, whilst noting improvement in patient symptoms, was no...

AbbVie’s RINVOQ now indicated for paediatric arthritis ...

AbbVie's RINVOQ is now indicated for polyarticular juvenile idiopathic arthritis...

FDA approves Moderna’s RSV vaccine mRESVIA

Moderna has secured approval from the US Food and Drug Administration (FDA) for ...

ASCO24: Can Ambrx’s novel ADC break into the metastatic...

The choice of control means that a US or European approval for Ambrx's ARX788 ma...

ASCO 2024: American Cancer Society and ASCO combine can...

The American Cancer Society (ACS) and the American Society of Clinical Oncology ...

ASCO 2024: Tagrisso approaches standard of Care status ...

At the ASCO annual meeting, Tagrisso showed an improvement in progression free s...

Lilly strikes deal with QurAlis for preclinical ALS can...

QRL-204 is designed to restore UNC13A function, a gene identified as a risk fact...

GRIT and Quangang announce IL-2 T-cell therapy partnership

GRIT has formed a strategic partnership with Quangang Pharmaceutical (Quangang) ...